Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection

Aim The risk of hepatitis B virus (HBV) reactivation with immune checkpoint inhibitors (ICIs) is an important issue that has not yet been fully investigated. ICI is also expected to have an antiviral effect on HBV due to its immune tolerance inhibitory effect. We herein investigated the risk of HBV...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology research 2022-09, Vol.52 (9), p.754-761
Hauptverfasser:	Hagiwara, Satoru, Nishida, Naoshi, Ida, Hiroshi, Ueshima, Kazuomi, Minami, Yasunori, Takita, Masahiro, Aoki, Tomoko, Morita, Masahiro, Chishina, Hirokazu, Komeda, Yoriaki, Yoshida, Akihiro, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Kudo, Masatoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	antiviral effect chemotherapy Chronic infection Drug development Hepatitis B Hepatitis B surface antigen hepatitis B virus immune checkpoint inhibitor Immune checkpoint inhibitors Immunological tolerance immunosuppressive therapy Patients Prophylaxis reactivation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!